Clarity Pharmaceuticals 

$1.6800
37
+$0.05+3.07% Friday 17:50

Statistics

Day High
1.7
Day Low
1.63
52W High
3.6
52W Low
1.232
Volume
500
Avg. Volume
12,490
Mkt Cap
626.59M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

27AugExpected
Q4 2023
Q2 2024
Q3 2024
Q4 2024
Q2 2025
Q4 2025
Q2 2026
-0.15
-0.11
-0.08
-0.05
Expected EPS
-0.1458188033643561
Actual EPS
-0.1201747638058814

Financials

-Profit Margin
Unprofitable
2019
2021
2022
2023
2024
2025
0Revenue
-111.27MNet Income

People Also Follow

This list is based on the watchlists of people on Stock Events who follow CLRPF. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novartis
NVS
Mkt Cap292.35B
Novartis is a global healthcare company that operates in the pharmaceuticals sector, directly competing with Clarity Pharmaceuticals in the development and marketing of therapeutic products.
Pfizer
PFE
Mkt Cap159.36B
Pfizer is a large pharmaceutical company with a broad range of products that compete in various therapeutic areas covered by Clarity Pharmaceuticals.
Merck
MRK
Mkt Cap366B
Merck & Co., Inc. is a global healthcare company that develops medicines, vaccines, biologic therapies, and animal health products, competing across several of Clarity Pharmaceuticals' focus areas.
Johnson & Johnson
JNJ
Mkt Cap645.95B
Johnson & Johnson is a diversified healthcare giant that competes with Clarity Pharmaceuticals through its pharmaceutical division, particularly in oncology and immunology.
Abbvie
ABBV
Mkt Cap451.46B
AbbVie operates in the pharmaceutical industry, focusing on immunology, oncology, and virology, which overlaps with Clarity Pharmaceuticals' therapeutic areas.
AMGEN
AMGN
Mkt Cap233.78B
Amgen is a biotechnology company focused on cardiovascular disease, oncology, bone health, neuroscience, nephrology, and inflammation, competing with Clarity Pharmaceuticals in several key areas.
Bristol-Myers Squibb
BMY
Mkt Cap136B
Bristol Myers Squibb is a global biopharmaceutical company with a focus on discovering, developing, and delivering innovative medicines that compete with Clarity Pharmaceuticals' product lines.
Gilead Sciences
GILD
Mkt Cap180.64B
Gilead Sciences is a biopharmaceutical company that discovers, develops, and commercializes innovative therapeutics in areas of unmet medical need, directly competing with Clarity Pharmaceuticals.
Astrazeneca
AZN
Mkt Cap252.33B
AstraZeneca is a global, science-led biopharmaceutical business that focuses on the discovery, development, and commercialization of prescription medicines, including those in areas competing with Clarity Pharmaceuticals.
Roche
RHHBY
Mkt Cap334.28B
Roche Holding AG is a leader in research-focused healthcare with strengths in pharmaceuticals and diagnostics, competing in therapeutic areas relevant to Clarity Pharmaceuticals.

About

Clarity Pharmaceuticals Ltd, a clinical stage radiopharmaceutical company, engages in research and development of radiopharmaceuticals products for oncology in Australia and the United States. The company's lead product is SAR-bisPSMA, a theranostic radiopharmaceutical for the treatment of Prostate Specific Membrane Antigen (PSMA) cancer. It also develops SAR-Bombesin, a pan cancer theranostic radiopharmaceutical to treat prostate, breast, ovarian, urinary, small cell lung cancer, as well as glioblastoma and gastrointestinal stromal tumours; and SARTATE, a theranostic radiopharmaceutical for the treatment of somatostatin receptor 2 (SSTR2) cancer. The company was incorporated in 2010 and is based in Sydney, Australia.
Show more...
CEO
Dr. Alan John Taylor Ph.D.
Country
Australia
ISIN
AU0000165375
WKN
000A3CV2W

Listings

0 Comments

Share your thoughts

FAQ

What is Clarity Pharmaceuticals stock price today?
The current price of CLRPF is $1.68 USD — it has increased by +3.07% in the past 24 hours. Watch Clarity Pharmaceuticals stock price performance more closely on the chart.
What is Clarity Pharmaceuticals stock ticker?
Depending on the exchange, the stock ticker may vary. For instance, on OTC Link exchange Clarity Pharmaceuticals stocks are traded under the ticker CLRPF.
Is Clarity Pharmaceuticals stock price growing?
CLRPF stock has fallen by -9.19% compared to the previous week, the month change is a -18.05% fall, over the last year Clarity Pharmaceuticals has showed a -20.75% decrease.
What is Clarity Pharmaceuticals market cap?
Today Clarity Pharmaceuticals has the market capitalization of 626.59M
When is the next Clarity Pharmaceuticals earnings date?
Clarity Pharmaceuticals is going to release the next earnings report on March 04, 2027.
What were Clarity Pharmaceuticals earnings last quarter?
CLRPF earnings for the last quarter are -0.09 USD per share, whereas the estimation was -0.1 USD resulting in a +17.59% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is Clarity Pharmaceuticals revenue for the last year?
Clarity Pharmaceuticals revenue for the last year amounts to 0 USD.
What is Clarity Pharmaceuticals net income for the last year?
CLRPF net income for the last year is -111.27M USD.
In which sector is Clarity Pharmaceuticals located?
Clarity Pharmaceuticals operates in the Health & Wellness sector.
When did Clarity Pharmaceuticals complete a stock split?
Clarity Pharmaceuticals has not had any recent stock splits.
Where is Clarity Pharmaceuticals headquartered?
Clarity Pharmaceuticals is headquartered in Sydney, Australia.